On Friday, Shares of Merck & Co. Inc. (NYSE:MRK), lost -2.01% to $51.59.
Merck & Co., known as MSD in the United States and Canada, recently declared results from new analyses from the IMPROVE-IT study.
“IMPROVE-IT presents us with the opportunity to look at cardiovascular outcomes data for patients treated with the combination of simvastatin and ezetimibe (VYTORIN) and allows us to look at the important aspect of long-term safety and efficacy under controlled conditions,” said Dr. Michael A. Blazing, Duke Department of Medicine.
VYTORIN (ezetimibe and simvastatin) and ZETIA (ezetimibe) are presently indicated for use together with a healthy diet to reduce elevated LDL cholesterol in patients with hyperlipidemia. The current U.S. Prescribing Information for both products states that the effect of ezetimibe on cardiovascular morbidity and mortality, alone or incremental to statin therapy, has not been determined. Merck has presented the data from the IMPROVE-IT study to the U.S. Food and Drug Administration to support a new indication for reduction of cardiovascular events for ZETIA and VYTORIN.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
Shares of Noble Corporation plc (NYSE:NE), declined -3.15% to $12.30, during its last trading session.
Noble Corporation declared that David W. Williams, Chairman, President and Chief Executive Officer, Noble Corporation, will present at the Barclays Capital CEO Energy-Power Conference in New York City on Wednesday, September 9, 2015, starting at 8:25 a.m. U.S. Eastern Daylight Time.
Noble Corporation plc operates as an offshore drilling contractor for the oil and gas industry worldwide. It owns and operates a fleet of mobile offshore drilling units.
Finally, CVS Health Corporation (NYSE:CVS), ended its last trade with -1.45% loss, and closed at $100.12.
CVS Health Corporation marked the first anniversary of ending tobacco sales at CVS/pharmacy by releasing new data showing a measurable reduction in cigarette purchases over the past year. The company also declared it is renewing its commitment to creating a tobacco-free generation through a joint initiative between CVS Health, its Foundation and Scholastic to launch a school-based tobacco-prevention program.
“One year ago, we stopped selling tobacco products because it conflicted with our purpose of assisting people on their path to better health,” said Troyen A. Brennan, M.D., M.P.H., Chief Medical Officer, CVS Health. “Recently, we are excited to release new data demonstrating the positive impact our decision has had on public health overall as shown by a measurable decrease in the number of cigarette purchases across all retailers.”
The study, conducted by the CVS Health Research Institute, evaluated cigarette pack purchases at drug, food, big box, dollar, convenience and gas station retailers in the eight months after CVS/pharmacy stopped selling tobacco products. The study found an additional one percent reduction in cigarette pack sales in states where CVS/pharmacy had a 15 percent or greater share of the retail pharmacy market, contrast to states with no CVS/pharmacy stores. Over the same eight-month period, the average smoker in these states purchased five fewer cigarette packs and, in total, about 95 million fewer packs were sold.
Further bolstering the impact of CVS/pharmacy’s tobacco removal, the CVS Health Research Institute study showed a four percent improvement in nicotine patch purchases in the states with a CVS/pharmacy market share of 15 percent of more, in the period right away following the end of tobacco sales. This indicates that there was also a positive effect on attempts to quit smoking.
CVS Health Corporation, together with its auxiliaries, provides integrated pharmacy health care services in the United States. The company operates through Pharmacy Services and Retail Pharmacy segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
